What some investors might not know is that Geron turned 23 years old this year. And in all that time, it has never had a drug reach the market. Most biotechs in a similar situation would have gone ...

Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Geron is about to release its quarterly ...

For a company that didn't conduct any of its own clinical trials in 2013, Geron sure had a banner year, hitting a strong share-price triple and then some. GERN Chart GERN data by YCharts . The ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Seeing Geron Corporation (NASDAQ: GERN) as one of the top ...

Here's why biotech Geron is a prime buyout target. And what makes this dramatic turnaround so impressive is that most industry insiders believed Geron was doomed after the failure of its lead brain ...

Let's look forward to this company's next earnings report. Geron is arguably best known not for what it did do but what it didn't do. Having originally been involved in stem-cell research, Geron ...